Journals / Bakırköy Tıp Dergisi / 2010 / Cilt: 6 - Sayı: 2

Use of botulinum toxin in urology: A rising trend in recent year

Ürolojide botulinum toksini kullanımı: Son yılların yükselen akımı

Pages
49–54
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

So to reach a better conclusion, controlled and validated studies with well-defined patient populations are necessary.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:When injected intramuscularly, Botulinum toxin, is a “ive, presynaptic and reversible neuromuscular blocking agent.
📊
Key Findings & Data:Different disciplines have used this toxin to treat muscular hypertonicity.
💡
Conclusion & Impact:So to reach a better conclusion, controlled and validated studies with well-defined patient populations are necessary.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

When injected intramuscularly, Botulinum toxin, is a “ive, presynaptic and reversible neuromuscular blocking agent. Different disciplines have used this toxin to treat muscular hypertonicity. In recent years, urologists have a tendency to use Botulinum toxin especially in neurologically oriented lower urinary tract diseases and functional pathologies like benign prostatic hyperplasia as an effective and less invasive treatment alternative. In a wide variety of patients with bladder outlet obstruction or acontractile bladder, the treatment is based on decreasing the outlet resistance. Spontaneous micturition may be possible if the treatment is successful. Botulinum toxin injection into detrusor muscle, was first applied, in children with meningomyelocele and patients with spinal cord injury, in order to treat neurogenic detrusor overactivity, and satisfactory results were reached. Validated studies have been recently conducted on detrusor sphincter dyssynergia and detrusor overactivity. Further possible indications for use of this toxin in urology are motor and sensory urge urethrospasm spasticity of the pelvic floor chronic prostatic pain. But, for none of these diseases, distinct treatment doses are defined. So to reach a better conclusion, controlled and validated studies with well-defined patient populations are necessary.

Özet

Botulinum toksini, intramuskuler olarak enjekte edildiğinde geri dönüşümlü ve selektif presinaptik bir nöromuskuler bloke edici ajandır. Farklı bilim dalları bu toksini temelde muskuler hiperkontraksiyon tedavisinde kullanmışlardır. Son yıllarda ürologlar, Botulinum toksinini özellikle nörojenik kaynaklı alt üriner sistem hastalıkları ve benign prostat hiperplazisi gibi fonksiyonel patolojilerin tedavisinde, daha az invaziv ve etkili bir alternatifi olarak önemsemeye başlamışlardır. Bu anlamda, başlıca kullanım alanları çeşitli mesane obstrüksiyonları ve akontraktil mesaneli hastalarda çıkım direncinin azaltılması olarak belirlenmiştir. Tedavinin başarılı olması halinde, spontan işeme sağlanabilmektedir. Detrüsör kasına botulinum toksin enjeksiyonu ilk olarak meningomyeloselli çocuklarda ve spinal kord yaralanması olan hastalarda nörojenik detrusor aktivitesini tedavi etmek için denenmiştir ve başarılı olmuştur. Detrusor sfinkter dissinerjisi ve detrusor overaktivitesinde kullanımı ile ilgili olarak son yıllarda valide edilmiş çalışmalar yayınlanmıştır. Bu ilacın ürolojide muhtemel diğer kullanım alanları motor ve sensoryel urge, üretrospazm, pelvik taban spastisitesi ve kronik prostatik ağrı olarak özetlenebilir. Ancak tüm bu hastalıklar için net tedavi dozları halen tartışmalıdır. Dolayısıyla, iyi tanımlanmış hasta populasyonlarıyla birlikte geniş çaplı ve valide edilmiş yeni çalışmalara ihtiyaç vardır.

🔖

Cite This Article

TOKGÖZ, H., DÖNMEZ, İ. H., MUNGAN, N. A. (2010). Use of botulinum toxin in urology: A rising trend in recent year. Bakırköy Tıp Dergisi, Cilt: 6 - Sayı: 2, 49–54. https://ajindex.com/articles/132904

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (17)

  1. Wheeler JS Jr, Walter JS, Chintam RS, Rao S. Botulinum toxin injections for voiding dysfunction following SCI. J Spinal Cord Med 1988; 21: 227-229
  2. Borodic GE, Joseph M, Fay L, Cozzolino D, Ferrante RJ. Botulinum A toxin for the treatment of spasmodic torticollis: dysphagia and regional toxin spread. Head Neck 1990; 12: 392
  3. Lazzeri M. New pharmacological tools. Urodynamica 2003; 13: 67-73
  4. Nolan J, Chalkiadis GA, Low J, Olesch CA, Brown TC. Anaesthesia and pain management in cerebral palsy. Anaesthesia 2000; 55: 32-41
  5. Simpson LL. Molecular pharmacology of botulinum toxin and tetanus toxin. Ann Rev Pharmacol Toxicol 1986; 26: 427-453
  6. Brashear A, Lew MF, Dykstra DD, et al. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A- responsive cervical dystonia. Neurology 1999; 53: 1439-1446
  7. Brin BF, Lew MF, Adler CH, et al. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-resistant cervical dystonia. Neurology 1999; 53: 1431-1438
  8. Sloop RR, Cole BA, Escutin RO. Human response to botulinum toxin injection: type B compared with type A. Neurology 1997; 49: 189- 194
  9. Aoki KR. Pharmacology and immunology of botulinum toxin serotypes. J Neurol 2001; 248: 3-10
  10. Coffield JA, Simpson LL. The site and mechanism of action of botulinum neurotoxin. In: Jankovic J, Hallet M (Eds). Therapy with botulinum toxin. New York: Marcel Dekker 1994; p. 3-13
  11. MacKenzie I, Burnstock G, Dolly JO. The effects of purified botulinum neurotoxin type A on cholinergic, adrenergic and non-adrenergic, atropine-resistant autonomic neuromuscular transmission. Neuroscience 1982; 74: 997-1006
  12. Thwaini A, Shergill I, Radhakrishnan S, Chinegwundoh F, Thwaini H. Botox in urology. Int Urogynecol J Pelvic Floor Dysfunct 2006; 17: 536-540
  13. Schantz E. Historical perspective. In: Jankovic J, Hallet M (Eds). Therapy with botulinum toxin. New York: Marcel Dekker Inc; 1994, p xxiii-xxvi
  14. Schantz E, Johnson EA. Botulinum toxin: the story of its development for the treatment of human disease. Perspect Biol Med 1997; 4: 317-327
  15. Schantz E, Johnson E. Preparation and characterization of botulinum toxin type A for human treatment. In: Jankovic J, Hallet M (Eds). Therapy with botulinum toxin. New York: Marcel Dekker Inc; 1994. p. 41-49
  16. Scott AB, Rosenbaum A, Collins CA. Pharmacologic weakening of extraocular muscles. Invest Ophtalmol Vis Sci 1973; 12: 924-927
  17. Scott AB. Botulinum toxin injection of eyemuscles to correct st